Hit to lead development of imidazopyridine containing compounds as treatment for babesiosis

$191,875P20FY2025GMNIH

University Of Vermont & St Agric College, Burlington VT

Investigators

Linked publications, trials & patents

Paper 39677596 Paper 39480886 Paper 39132478 Paper 38567972 Paper 38535566 Paper 38484538 Paper 38427895 Paper 38283383 Paper 38154065 Paper 38085791 Paper 38048378 Paper 37992129 Paper 37857996 Paper 37819784 Paper 37776876 Paper 37771961 Paper 37333724 Paper 37023420 Paper 36765151 Paper 36477293 Paper 35653307 Paper 35544643 Paper 35222425 Paper 35130315 Paper 35058348 Paper 35025926 Paper 34904667 Paper 34862752 Paper 34741103 Paper 34453881 Paper 34400502 Paper 34367312 Paper 34285133 Paper 34031380 Paper 33880478 Paper 33862710 Paper 33791699 Paper 33750152 Paper 33684067 Paper 33676971 Paper 33597214 Paper 33566810 Paper 33377126 Paper 33327868 Paper 33315576 Paper 33198707 Paper 33180773 Paper 33143594 Paper 33080218 Paper 33072323 Paper 33048967 Paper 33033179 Paper 33006983 Paper 32971144 Paper 32940644 Paper 32869043 Paper 32830128 Paper 32773498 Paper 32743592 Paper 32645081 Paper 32511328 Paper 32457212 Paper 32382253 Paper 32277815 Paper 32265929 Paper 32251996 Paper 32196500 Paper 32157282 Paper 32112750 Paper 32088018 Paper 32067944 Paper 31916965 Paper 31708586 Paper 31689144 Paper 31607603 Paper 31471206 Paper 31048709 Paper 31015448 Paper 30996133 Paper 30894487 Paper 30857944 Paper 30770931 Paper 30745384 Paper 30723081 Paper 30576507 Paper 30559138 Paper 30356267 Paper 30297368 Paper 30010906

Abstract

babesiosis, the illness caused by the tickborne malaria-like parasite Babesia, is an emerging infectious disease for which existing antimicrobials are inadequate in immunocompromised hosts. There is a critical need for development of new therapeutics. A series of 28 imidazopyridine-containing compounds (ICCs) which have been identified as highly potent in vitro growth inhibitors of babesia duncani can potentially fill this need.

View original record on NIH RePORTER →